BeiGene Ltd (6160) AI Stock Analysis

• Market Cap: HK$321.99B
• Dividend Yield: N/A
• Average Volume (3M): 5.08M
• Price to Earnings (P/E): 634.4
• Beta (1Y): 1.05
• Revenue Growth: 49.63%
• EPS Growth: N/A
• Country: HK
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.65
• Shares Outstanding: 1,540,976,000
• 10 Day Avg. Volume: 3,608,600
• 30 Day Avg. Volume: 5,076,742
• PEG Ratio: 1.08
• Price to Book (P/B): 5.77
• Price to Sales (P/S): 5.05
• P/FCF Ratio: -28.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$239.97
• Price Target Upside: 30.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: HK$194.00 ▲(5.15% Upside)

BeiGene Ltd's stock score is primarily influenced by its strong financial performance, particularly in revenue growth and cash flow improvement. However, the technical analysis indicates a bearish trend, and the valuation suggests potential overvaluation with a very high P/E ratio. These factors combined result in a moderate overall stock score.

Positive Factors

Revenue Growth

The strong revenue growth rate indicates a positive trajectory in sales, suggesting the company's products are gaining market traction, which could lead to sustained financial performance.

Cash Flow Improvement

Significant improvement in cash flow generation enhances financial flexibility, allowing for strategic investments and reducing reliance on external financing.

Strong Gross Profit Margin

A high gross profit margin reflects efficient cost management, which supports profitability and allows for reinvestment in R&D and market expansion.

Negative Factors

Profitability Challenges

Despite revenue growth, the company struggles to convert sales into profits, which may hinder its ability to reinvest in growth and innovation.

Negative Return on Equity

A negative return on equity indicates challenges in generating returns for shareholders, potentially impacting investor confidence and long-term capital raising.

High Valuation Risk

An extremely high P/E ratio suggests the stock is priced for significant growth, which could be risky if growth expectations are not met, impacting long-term investor sentiment.

BeiGene Ltd Business Overview & Revenue Model

Company Description

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

How the Company Makes Money

BeiGene generates revenue through multiple streams, primarily from the sales of its oncology therapies, which include both marketed products and those under development. The company has established partnerships and collaborations with other biopharmaceutical companies, allowing it to leverage shared resources and expertise in drug development. Additionally, BeiGene receives milestone payments and royalties from these partnerships upon achieving specific clinical or regulatory objectives. Their revenue model is bolstered by a robust pipeline of investigational drugs, which, if successful in clinical trials, can lead to substantial future earnings from both direct sales and licensing agreements.

BeiGene Ltd Financial Statement Overview

Summary

BeiGene Ltd demonstrates strong revenue growth and efficient cost management, as seen in its high gross profit margin. However, the company faces challenges in profitability and return on equity, which are areas for improvement. The balance sheet is stable with a conservative leverage approach, and cash flow generation is improving significantly, which bodes well for future financial flexibility.

Income Statement

BeiGene Ltd has shown a strong revenue growth rate of 9.0% in the TTM, indicating a positive trajectory in sales. The gross profit margin is impressive at 85.5%, reflecting efficient cost management. However, the company struggles with profitability, as evidenced by a negative net profit margin of -3.9% and EBIT margin of -2.2%. This suggests that while revenue is growing, the company is not yet converting this into net profits.

Balance Sheet

The balance sheet of BeiGene Ltd is relatively stable with a manageable debt-to-equity ratio of 0.27, indicating a conservative approach to leveraging. The equity ratio stands at 54.1%, showing a strong equity base. However, the return on equity is negative at -5.1%, highlighting challenges in generating returns for shareholders.

Cash Flow

The cash flow statement shows significant improvement, with a free cash flow growth rate of 181.4% in the TTM, indicating enhanced cash generation capabilities. The operating cash flow to net income ratio is 0.26, suggesting that the company is generating cash from operations, although the free cash flow to net income ratio of 0.29 indicates room for improvement in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.97B	3.81B	2.46B	1.42B	1.18B	308.87M
Gross Profit	4.29B	3.22B	2.08B	-511.06M	-447.86M	-1.06B
EBITDA	338.62M	-396.44M	-1.12B	-1.72B	-1.39B	-1.63B
Net Income	68.55M	-644.79M	-881.71M	-2.00B	-1.46B	-1.62B
Balance Sheet
Total Assets	7.63B	5.92B	5.81B	6.38B	8.65B	5.60B
Cash, Cash Equivalents and Short-Term Investments	4.04B	2.63B	3.17B	4.53B	6.62B	4.65B
Total Debt	1.02B	1.08B	930.18M	596.67M	694.64M	561.96M
Total Liabilities	3.50B	2.59B	2.27B	2.00B	2.40B	1.73B
Stockholders Equity	4.13B	3.33B	3.54B	4.38B	6.24B	3.87B
Cash Flow
Free Cash Flow	463.90M	-669.77M	-1.75B	-1.97B	-1.61B	-1.51B
Operating Cash Flow	785.39M	-140.63M	-1.16B	-1.50B	-1.30B	-1.28B
Investing Cash Flow	-331.43M	-548.35M	60.00M	1.08B	640.66M	-3.17B
Financing Cash Flow	958.00M	193.45M	416.48M	-18.97M	3.64B	5.20B

BeiGene Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 184.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6160, the sentiment is Positive. The current price of 184.5 is below the 20-day moving average (MA) of 187.61, below the 50-day MA of 195.68, and above the 200-day MA of 175.76, indicating a bullish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 56.49 is Neutral, neither overbought nor oversold. The STOCH value of 87.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6160.

BeiGene Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3692	73 Outperform	HK$251.89B	47.92	16.09%	0.97%	8.68%	0.82%
2359	69 Neutral	HK$323.45B	19.96	25.65%	1.84%	11.55%	64.46%
2269	63 Neutral	HK$153.19B	33.25	9.79%	―	16.90%	63.11%
1801	61 Neutral	HK$154.90B	120.22	8.41%	―	52.78%	―
6160	54 Neutral	HK$321.99B	634.41	-4.94%	―	49.63%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BeiGene Ltd Corporate Events

BeOne Medicines Grants 53,322 RSUs Under Incentive Plan to 155 Recipients

BeOne Medicines has granted 53,322 restricted share units (RSUs), equivalent to 693,186 underlying shares or about 0.04% of its issued share capital, to 155 grantees under its 2016 Share Option and Incentive Plan. The awards, which include a small allocation to an external scientific adviser, are structured to vest mainly in 25% annual tranches over four years (with certain specific vesting schedules and potential acceleration on termination or change of control), underscoring the company’s use of equity incentives to retain talent and align employees’ and advisers’ interests with long-term shareholder value while causing only minimal share dilution.

The most recent analyst rating on (HK:6160) stock is a Hold with a HK$194.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Ltd. Grants 21,274 RSUs to Employees

BeOne Medicines Ltd., a Swiss corporation listed on the Hong Kong Stock Exchange, announced the grant of 21,274 Restricted Share Units (RSUs) to 147 employees under its 2016 Share Option and Incentive Plan. This grant represents approximately 0.02% of the company’s total issued shares. The RSUs will vest over four years, subject to continued employment, with specific conditions for accelerated vesting in certain cases. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.

The most recent analyst rating on (HK:6160) stock is a Hold with a HK$211.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Grants RSUs to Employees

BeOne Medicines Ltd., a corporation incorporated under the laws of Switzerland, announced the grant of Restricted Share Units (RSUs) under its 2016 Share Option and Incentive Plan. On November 10, 2025, the company’s compensation committee granted a total of 16,463 RSUs, equivalent to 214,019 underlying shares, to 143 employees, representing approximately 0.01% of the total issued shares. The RSUs will vest over four years, with specific conditions for accelerated vesting. This move is part of BeOne’s strategy to incentivize its workforce and align their interests with the company’s growth objectives.

The most recent analyst rating on (HK:6160) stock is a Hold with a HK$222.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Announces Q3 2025 Financial Results and Business Updates

BeOne Medicines Ltd., a Swiss-incorporated company, announced its unaudited financial results for the third quarter and nine months ending September 30, 2025. The company has provided business updates and revised its financial guidance for the full year. The results, prepared under U.S. GAAP, highlight key business milestones and expectations for continued global expansion and investment. The announcement also includes insights into BeOne’s strategic focus on achieving regulatory milestones and enhancing its market position with its drug candidates.

The most recent analyst rating on (HK:6160) stock is a Hold with a HK$186.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Ltd. Announces Form 10-Q Filing

BeOne Medicines Ltd., a company incorporated in Switzerland, has issued an overseas regulatory announcement regarding its Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarterly period ended September 30, 2025. The announcement highlights the company’s compliance with reporting requirements and provides details on its securities registered on The Nasdaq Global Select Market and The Stock Exchange of Hong Kong Limited. This filing underscores BeOne Medicines’ commitment to transparency and regulatory adherence, potentially reinforcing its credibility and stability in the market.

The most recent analyst rating on (HK:6160) stock is a Hold with a HK$186.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Secures Regulatory Waivers for Enhanced Flexibility

BeOne Medicines Ltd. has announced a series of waivers and exemptions from compliance with certain Hong Kong Stock Exchange Listing Rules and the Companies Ordinance. These include waivers related to the use of US GAAP, placings to connected persons, and collaboration agreements, among others. The company’s directors have taken responsibility for the accuracy of the information provided and have committed to updating the information sheet if there are material changes. This announcement highlights BeOne Medicines’ strategic moves to navigate regulatory requirements, potentially impacting its operational flexibility and stakeholder relations.

The most recent analyst rating on (HK:6160) stock is a Hold with a HK$186.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Ltd. to Announce Q3 2025 Financial Results

BeOne Medicines Ltd., a Swiss corporation, announced it will release its unaudited financial results for the third quarter of 2025 on November 6, 2025, following the trading hours of the Hong Kong Stock Exchange. The results will be reviewed by the audit committee on the same day, and a conference call with management will be held to discuss the financials, providing stakeholders an opportunity to engage with the company’s leadership.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$236.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

BeOne Medicines Ltd. Announces Name and Stock Short Name Change

BeOne Medicines Ltd., formerly known as BeiGene, Ltd., has officially changed its English company name and stock short name as part of its strategic rebranding efforts. The change, effective from May 27, 2025, reflects the company’s new identity and is confirmed by the Registrar of Companies in Hong Kong. The English stock short name for trading on the HKEX will be updated to ‘BEONE MEDICINES’ starting October 22, 2025, while the stock code remains ‘06160’. This rebranding is a significant step in the company’s evolution and may influence its market presence and stakeholder engagement.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$236.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.